GlycoMimetics, Inc. (GLYC)Â
Trading
Quantity
Profitability
Ownership
Largest Insider Buys in Sector
GLYC Insider Trading Activity
GLYC Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $83,159 | 3 | 25 |
Sells | $488,749 | 9 | 75 |
Related Transactions
| Rock Edwin | Chief Medical Officer | 2 | $78,825 | 0 | $0 | $78,825 |
| Hahn Brian M. | SVP Finance, CFO | 1 | $4,335 | 0 | $0 | $4,335 |
| Invus Public Equities, L.P. | 10 percent owner | 0 | $0 | 9 | $488,749 | $-488,749 |
About GlycoMimetics, Inc.
GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. It is developing uproleselan, an E-selectin inhibitor, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as in phase 3 trial to treat relapsed/refractory AML. In addition, the company is developing GMI-1359, which targets e-selectin and a chemokine receptor for the treatment of cancers that affect the bone and bone marrow, including solid tumors. It also develops various other programs, including GMI-1687, an antagonist of E-selectin to treat vaso-occlusive crisis; and galectin-3 antagonists, a carbohydrate-binding protein. The company has a cooperative research and development agreement with the National Cancer Institute; and a collaboration and license agreement with Apollomics (Hong Kong) Limited for the development and commercialization of uproleselan and GMI-1687. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Rockville, Maryland.
Insider Activity of GlycoMimetics, Inc.
Over the last 12 months, insiders at GlycoMimetics, Inc. have bought $83,159 and sold $488,749 worth of GlycoMimetics, Inc. stock.
On average, over the past 5 years, insiders at GlycoMimetics, Inc. have bought $2.17M and sold $2.74M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Rock Edwin (Chief Medical Officer) — $78,825. Hahn Brian M. (SVP Finance, CFO) — $4,335.
The last purchase of 115,000 shares for transaction amount of $30,717 was made by Rock Edwin (Chief Medical Officer) on 2024‑06‑21.
List of Insider Buy and Sell Transactions, GlycoMimetics, Inc.
| 2024-08-08 | Sale | Invus Public Equities, L.P. | 10 percent owner | 260,873 0.4135% | $0.19 | $50,009 | +36.11% | |
| 2024-08-07 | Sale | Invus Public Equities, L.P. | 10 percent owner | 61,488 0.0996% | $0.18 | $11,197 | +46.39% | |
| 2024-08-06 | Sale | Invus Public Equities, L.P. | 10 percent owner | 55,732 0.0882% | $0.18 | $10,188 | +41.99% | |
| 2024-08-05 | Sale | Invus Public Equities, L.P. | 10 percent owner | 164,523 0.2612% | $0.19 | $30,996 | +37.75% | |
| 2024-08-02 | Sale | Invus Public Equities, L.P. | 10 percent owner | 286,200 0.4383% | $0.20 | $57,354 | +24.68% | |
| 2024-08-01 | Sale | Invus Public Equities, L.P. | 10 percent owner | 63,564 0.0987% | $0.22 | $13,743 | +16.94% | |
| 2024-07-30 | Sale | Invus Public Equities, L.P. | 10 percent owner | 756,835 1.1897% | $0.22 | $167,185 | +15.78% | |
| 2024-07-29 | Sale | Invus Public Equities, L.P. | 10 percent owner | 363,949 0.5697% | $0.24 | $85,637 | +8.19% | |
| 2024-07-26 | Sale | Invus Public Equities, L.P. | 10 percent owner | 258,335 0.4016% | $0.24 | $62,440 | +4.56% | |
| 2024-06-21 | Rock Edwin | Chief Medical Officer | 115,000 0.1787% | $0.27 | $30,717 | +0.66% | ||
| 2024-06-20 | Rock Edwin | Chief Medical Officer | 190,000 0.2799% | $0.25 | $48,108 | +3.54% | ||
| 2024-06-18 | Hahn Brian M. | SVP Finance, CFO | 17,500 0.0252% | $0.25 | $4,335 | +6.90% | ||
| 2023-09-22 | Rock Edwin | Chief Medical Officer | 30,403 0.0463% | $1.38 | $41,956 | -0.71% | ||
| 2023-09-21 | Rock Edwin | Chief Medical Officer | 35,000 0.0544% | $1.38 | $48,300 | +2.17% | ||
| 2023-05-17 | Sale | Hahn Brian M. | SVP Finance, CFO | 3,700 0.0059% | $1.95 | $7,215 | -15.69% | |
| 2023-05-10 | JUNIUS DANIEL M | director | 30,000 0.0441% | $1.56 | $46,800 | -1.14% | ||
| 2023-05-08 | Johnson Bruce S | SVP & Chief Commercial Officer | 13,500 0.0237% | $1.57 | $21,195 | +18.24% | ||
| 2023-02-24 | Invus Public Equities, L.P. | 10 percent owner | 100,000 0.1667% | $1.70 | $170,000 | -5.03% | ||
| 2023-02-23 | Invus Public Equities, L.P. | 10 percent owner | 200,000 0.3399% | $1.75 | $350,760 | -5.85% | ||
| 2023-02-22 | Invus Public Equities, L.P. | 10 percent owner | 150,000 0.2504% | $1.79 | $268,995 | -9.55% |
Insider Historical Profitability
| Invus Public Equities, L.P. | 10 percent owner | 6317565 9.7926% | $1.54M | 8 | 9 | <0.0001% |
| Rock Edwin | Chief Medical Officer | 680403 1.0547% | $166,222.45 | 7 | 0 | <0.0001% |
| Hahn Brian M. | SVP Finance, CFO | 70643 0.1095% | $17,258.08 | 2 | 3 | +31.85% |
| BVF PARTNERS L P/IL | 10 percent owner | 4980812 7.7205% | $1.22M | 3 | 0 | <0.0001% |
| BARRIS PETER J | 10 percent owner | 4702791 7.2896% | $1.15M | 1 | 2 | <0.0001% |
| NEW ENTERPRISE ASSOCIATES 10 L P | 10 percent owner | 4702791 7.2896% | $1.15M | 1 | 2 | <0.0001% |
| BARRETT M JAMES | 4702791 7.2896% | $1.15M | 1 | 2 | <0.0001% | |
| NEW ENTERPRISE ASSOCIATES 13 LP | 10 percent owner | 4093377 6.345% | $1M | 1 | 0 | <0.0001% |
| SANDELL SCOTT D | director | 2237196 3.4678% | $546,546.98 | 1 | 8 | <0.0001% |
| HENOS MICHAEL A | director | 469454 0.7277% | $114,687.61 | 2 | 4 | +27.18% |
| Magnani John L. | SVP of Research, CSO | 366078 0.5674% | $89,432.86 | 1 | 4 | +31.85% |
| King Rachel K. | President, CEO | 356064 0.5519% | $86,986.44 | 0 | 1 | |
| Thackray Helen M. | SVP Clinical Development, CMO | 148615 0.2304% | $36,306.64 | 0 | 9 | |
| Johnson Bruce S | SVP & Chief Commercial Officer | 138980 0.2154% | $33,952.81 | 1 | 0 | +18.24% |
| JUNIUS DANIEL M | director | 93250 0.1445% | $22,780.98 | 5 | 0 | +18.6% |
| Andrews Patricia S | director | 45250 0.0701% | $11,054.58 | 1 | 0 | <0.0001% |
| Girard Armand | SVP, Chief Business Officer | 29161 0.0452% | $7,124.03 | 1 | 1 | +31.85% |
| Semerjian Harout | Chief Executive Officer | 25000 0.0388% | $6,107.50 | 1 | 0 | +31.85% |
| PEARSON TIMOTHY R | director | 24650 0.0382% | $6,022.00 | 1 | 0 | +31.85% |
| Goldberg Mark Alan | director | 11497 0.0178% | $2,808.72 | 1 | 0 | +23.55% |
Historical Insider Profitability vs. Competitors
$550,024 | 37 | -2.68% | $18.2M | |
$296,936 | 37 | -18.12% | $17.91M | |
GlycoMimetics, Inc. (GLYC) | $85,897,100 | 36 | 2.47% | $15.76M |
$217,684 | 34 | 1.61% | $18.05M | |
$383,884 | 32 | -25.10% | $16.67M | |
$4,368,362 | 28 | -22.35% | $16.6M | |
$226,127 | 22 | -27.62% | $17.69M | |
$555,628 | 21 | 43.52% | $17.72M | |
$112,810,270 | 18 | -1.20% | $14.67M | |
$37,194,483 | 17 | -51.30% | $16.85M | |
$2,553,853 | 17 | 16.69% | $15.59M | |
$36,538,405 | 10 | -21.99% | $14.47M | |
$189,648 | 9 | -52.20% | $14.31M | |
$2,060,158 | 5 | -21.35% | $14.55M | |
$26,000,000 | 5 | -56.00% | $15.4M | |
$1,028,395 | 4 | -11.91% | $16.91M | |
$31,190 | 2 | -14.18% | $14.97M | |
$245,940 | 2 | 31.12% | $14.99M | |
$5,512,500 | 1 | -7.91% | $14.86M |
GLYC Institutional Investors: Active Positions
| Increased Positions | 22 | +47.83% | 16M | +91.35% |
| Decreased Positions | 16 | -34.78% | 4M | -20.74% |
| New Positions | 16 | New | 16M | New |
| Sold Out Positions | 11 | Sold Out | 3M | Sold Out |
| Total Postitions | 52 | +13.04% | 30M | +70.62% |
GLYC Ownership Change vs Market
Institutional Investor Ownership
| Bvf Inc/Il | $2,577.00 | 14.68% | 9.54M | 0 | 0% | 2024-12-31 |
| Logos Global Management Lp | $1,458.00 | 8.31% | 5.4M | +5M | New | 2024-12-31 |
| Adage Capital Partners Gp, L.L.C. | $1,375.00 | 7.83% | 5.09M | +5M | New | 2024-12-31 |
| Vr Adviser, Llc | $810.00 | 4.62% | 3M | +3M | New | 2024-12-31 |
| Vanguard Group Inc | $721.00 | 4.11% | 2.67M | 0 | 0% | 2024-12-31 |
| Wellington Management Group Llp | $382.00 | 2.17% | 1.41M | +1M | New | 2024-12-31 |
| Blackrock, Inc. | $197.00 | 1.12% | 728,637 | +779 | +0.11% | 2024-12-31 |
| Geode Capital Management, Llc | $141.00 | 0.8% | 521,223 | 0 | 0% | 2024-12-31 |
| Jefferies Financial Group Inc. | $114.00 | 0.65% | 423,777 | +423,777 | New | 2024-12-31 |
| Adar1 Capital Management, Llc | $90.00 | 0.51% | 331,827 | +286,127 | +626.1% | 2024-12-31 |